{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:50:06Z","timestamp":1787698206475,"version":"build-2784847793"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.dld.2025.09.026","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T17:08:29Z","timestamp":1761412109000},"page":"74-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term safety of ustekinumab in Crohn\u2019s disease: Descriptive analysis from an observational post-authorisation safety study using I-CARE cohort data"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6618","authenticated-orcid":false,"given":"Laurent","family":"Peyrin-Biroulet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Nazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6090-491X","authenticated-orcid":false,"given":"Anna","family":"Sheahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Geldhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahlem","family":"Azzabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Baert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Mailhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1262-5688","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Rahier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Beaugerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2025.09.026_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)02586-2","article-title":"Crohn's disease","volume":"403","author":"Dolinger","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2025.09.026_bib0002","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/ncpgasthep0528","article-title":"Mechanisms of disease: pathogenesis of Crohn\u2019s disease and ulcerative colitis","volume":"3","author":"Sartor","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"Supplement_2","key":"10.1016\/j.dld.2025.09.026_bib0003","doi-asserted-by":"crossref","first-page":"ii64","DOI":"10.1093\/ecco-jcc\/jjab185","article-title":"Blockade of IL-23: what is in the pipeline?","volume":"16","author":"Parigi","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2025.09.026_bib0004","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izac199","article-title":"The pathogenicity and synergistic action of Th1 and Th17 cells in inflammatory bowel diseases","volume":"29","author":"Cao","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2025.09.026_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.09.026_bib0006","unstructured":"STELARA [package insert]. Horsham, PA, USA: Janssen Biotech, Inc; 2012."},{"key":"10.1016\/j.dld.2025.09.026_bib0007","unstructured":"STELARA [EPAR product information]. Beerse, Belgium: Janssen-Cilag International NV; 2023."},{"key":"10.1016\/j.dld.2025.09.026_bib0008","doi-asserted-by":"crossref","DOI":"10.1097\/MEG.0000000000002506","article-title":"Long-term effectiveness and safety of ustekinumab in Crohn's disease: a prospective cohort study","volume":"35","author":"Thomas","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.09.026_bib0009","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12876-022-02280-3","article-title":"Long-term effectiveness and safety of ustekinumab in bio-na\u00efve and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: a real-world multicenter Brazilian study","volume":"22","author":"Parra","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.dld.2025.09.026_bib0010","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izab357","article-title":"Long-term real-world effectiveness and safety of ustekinumab in Crohn's disease patients: the SUSTAIN study","volume":"28","author":"Chaparro","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2025.09.026_bib0011","doi-asserted-by":"crossref","DOI":"10.1111\/apt.14487","article-title":"Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience","volume":"47","author":"Wils","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.09.026_bib0012","doi-asserted-by":"crossref","DOI":"10.1111\/apt.15958","article-title":"Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry","volume":"52","author":"Iborra","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.09.026_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241242700","article-title":"Long-term real-world data of ustekinumab in Crohn's disease: the Stockholm ustekinumab study","volume":"17","author":"Bello","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.dld.2025.09.026_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2022.09.018","article-title":"I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease","volume":"21","author":"Peyrin-Biroulet","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.09.026_bib0015","unstructured":"Ibd CAncer and seRious infection in Europe: I-CARE. The major European longitudinal, observational multicenter & prospective cohort study in IBD. https:\/\/www.icare-ibd.com. Accessed January 20, 2025."},{"key":"10.1016\/j.dld.2025.09.026_bib0016","unstructured":"ClinicalTrials.gov. IBD cancer and serious infection in Europe (I-CARE). https:\/\/clinicaltrials.gov\/study\/NCT02377258. Accessed January 20, 2025."},{"key":"10.1016\/j.dld.2025.09.026_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/art.41754","article-title":"Nonserious infections in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"73","author":"Bechman","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.dld.2025.09.026_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2017.10.005","article-title":"Risk of serious infection in patients with psoriasis receiving biologic therapies: A prospective cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"138","author":"Yiu","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.dld.2025.09.026_bib0019","first-page":"73","article-title":"Ustekinumab in the treatment of Crohn's disease-A narrative review on clinical efficacy and safety profile","volume":"13","author":"Piecuch","year":"2025","journal-title":"Pharmacy (Basel)"},{"key":"10.1016\/j.dld.2025.09.026_bib0020","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/imj.16141","article-title":"Risk factors for malignancy and serious infection in patients with inflammatory bowel disease: a retrospective analysis","volume":"54","author":"Tassone","year":"2024","journal-title":"Intern Med J"},{"key":"10.1016\/j.dld.2025.09.026_bib0021","article-title":"Crohn's disease and the risk of cancer","volume":"32","author":"Carchman","year":"2019","journal-title":"Clin Colon Rectal Surg"},{"key":"10.1016\/j.dld.2025.09.026_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2013.441","article-title":"Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT\u2122 Registry","volume":"109","author":"Lichtenstein","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2025.09.026_bib0023","doi-asserted-by":"crossref","DOI":"10.1080\/00365521.2021.1924259","article-title":"Adult-onset inflammatory bowel disease and rate of serious infections compared to the general population: a nationwide register-based cohort study 2002-2017","volume":"56","author":"Ludvigsson","year":"2021","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2025.09.026_bib0024","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT\u2122 registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2025.09.026_bib0025","article-title":"Upadacitinib induction and maintenance therapy for Crohn's disease","volume":"388","author":"Jr","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2025.09.026_bib0026","doi-asserted-by":"crossref","DOI":"10.1080\/1744666X.2019.1646127","article-title":"Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases","volume":"15","author":"Holmer","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.dld.2025.09.026_bib0027","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000002047","article-title":"The real-world effectiveness and safety of ustekinumab in the treatment of Crohn's disease: results from the SUCCESS consortium","volume":"118","author":"Johnson","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2025.09.026_bib0028","doi-asserted-by":"crossref","DOI":"10.1111\/apt.16050","article-title":"Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and\/or thiopurines in patients with inflammatory bowel disease","volume":"52","author":"Chupin","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.09.026_bib0029","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izac171","article-title":"Risks of melanoma and nonmelanoma skin cancers pre- and post-inflammatory bowel disease diagnosis","volume":"29","author":"Narous","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2025.09.026_bib0030","article-title":"Comparative risk of serious infections with biologic and\/or immunosuppressive therapy in patients with inflammatory bowel diseases: A systematic review and meta-analysis","volume":"8","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.09.026_bib0031","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/jcm13010251","article-title":"Venous thromboembolism in patients with inflammatory bowel disease","volume":"13","author":"Dhaliwal","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.dld.2025.09.026_bib0032","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2009.322","article-title":"Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease","volume":"104","author":"Marehbian","year":"2009","journal-title":"Am J Gastroenterol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825011284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825011284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:50:43Z","timestamp":1770655843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865825011284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1590865825011284"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2025.09.026","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety of ustekinumab in Crohn\u2019s disease: Descriptive analysis from an observational post-authorisation safety study using I-CARE cohort data","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2025.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}